Regeneron faces securities lawsuits amid market challenges and strategic initiatives. Investors assess potential impacts and the company's ability to navigate headwinds.
Regeneron faces securities fraud lawsuits amid positive EU recommendation for Linvoseltamab. EYLEA and Dupixent remain key revenue drivers.
Regeneron (REGN) faces lawsuits amid EYLEA concerns, while an FDA review offers hope. Dupixent remains strong, but competition persists. The future hinges on innovation.
Regeneron faces securities lawsuits over EYLEA sales, while the FDA reviews odronextamab for lymphoma. Competitive pressures and pipeline developments shape investor outlook.
Regeneron faces lawsuits and EYLEA competition, but gene therapy offers hope. Investors must weigh risks and opportunities.
Regeneron (REGN) faces a securities lawsuit and EYLEA competition. Analysis of allegations, market impact, and strategic responses are crucial for investors.
Regeneron (REGN) is embroiled in a securities lawsuit over alleged Eylea pricing violations, with a critical lead plaintiff deadline on March 10, 2025.
Intraday update reveals mounting legal challenges, declining EYLEA sales, and heightened competitive pressures affecting REGN.
Regeneron Pharmaceuticals faces multiple securities lawsuits amid legal challenges and market pressure. Detailed analysis provided.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.